Physician profile
Mark A Passerman
NPI 1851404313
$959.68
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $110 · 2021: $122 · 2022: $243 · 2023: $167 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.87 | 2019-2023 | Ozempic |
| Astrazeneca Pharmaceuticals Lp | $139.16 | 2020-2024 | Airsupra, Breztri |
| Amgen INC. | $107.99 | 2019 | |
| Xeris Pharmaceuticals, INC. | $63.53 | 2023 | Keveyis |
| Novartis Pharmaceuticals Corporation | $55.20 | 2022 | |
| Abbott Laboratories | $52.81 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $46.14 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.05 | 2020-2021 | |
| Glaxosmithkline, LLC. | $32.56 | 2020-2021 | |
| Eisai INC. | $31.86 | 2021 | |
| Exact Sciences Corporation | $24.53 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $23.35 | 2021 | |
| Gilead Sciences, INC. | $20.81 | 2020 | |
| Merck Sharp & Dohme LLC | $18.42 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.64 | 2023 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $15.86 | 2019 | |
| Lilly USA, LLC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Passerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.